RESEARCH ARTICLE


A Novel Bioluminescent Protease Assay Using Engineered Firefly Luciferase



Susan S Wigdal, Jessica L Anderson, Gediminas J Vidugiris, John Shultz, Keith V Wood, Frank Fan*
Promega Corporation, 2800 Woods Hollow Road, Madison, WI 53711, USA


Article Metrics

CrossRef Citations:
0
Total Statistics:

Full-Text HTML Views: 836
Abstract HTML Views: 504
PDF Downloads: 174
Total Views/Downloads: 1514
Unique Statistics:

Full-Text HTML Views: 364
Abstract HTML Views: 244
PDF Downloads: 115
Total Views/Downloads: 723



© Wigdal et al.; Licensee Bentham Open.

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

* Address correspondence to this author at the Promega Corporation, 2800 Woods Hollow Road, Madison, WI 53711, USA; Tel: 608-277-2531; Fax: 608-298-4818; E-mail: frank.fan@promega.com


Abstract

Proteases play important roles in a variety of disease processes. Understanding their biological functions underpins the efforts of drug discovery. We have developed a bioluminescent protease assay using a circularly permuted form of firefly luciferase, wherein the native enzyme termini were joined by a peptide containing a protease site of interest. Protease cleavage of these mutant luciferases greatly activates the enzyme, typically over 100 fold. The mutant luciferase substrates are easily generated by molecular cloning and cell-free translation reactions and thus the protease substrates do not need to be chemically synthesized or purchased. The assay has broad applicability using a variety of proteases and their cognate sites and can sensitively detect protease activity. In this report we further demonstrate its utility for the evaluation of protease recognition sequence specificity and subsequent establishment of an optimized assay for the identification and characterization of protease inhibitors using high throughput screening.